![李斌[暨南大學碩士生導師]](/img/7/fc0/nBnauM3X3gDN4MDN4czMyIDN0UTMyITNykTO0EDMwAjMwUzL3MzLxEzLt92YucmbvRWdo5Cd0FmLwE2LvoDc0RHa.jpg "李斌[暨南大學碩士生導師]")
個人簡介
李斌博士，現任暨南大學生命科學技術學院副研究員，碩士生導師。於2001年和2003年在國家生命科學與技術人才培養基地（吉林大學/瀋陽藥科大學/中科院上海生物化學與細胞生物學研究所）獲得本科和碩士學位，於2009年在香港大學獲得博士學位。2015年作為優秀人才被引進到暨南大學生命與健康工程研究院任副研究員。 主要從事腫瘤生物學和功能蛋白質組學等相關領域的研究，包括功能蛋白質和microRNA的高通量篩選及其在腫瘤微環境和惡性腫瘤發生髮展中的生物學功能和作用機制，腫瘤幹細胞的分離和鑑定，腫瘤化療耐藥和腫瘤轉移的分子機制，以及靶向治療的探索和研究。在國際著名期刊（Clinical Cancer Research, Oncotarget, International journal of Cancer, Carcinogenesis, Molecular Cancer Therapeutics等）上發表多篇SCI收錄文章，多篇文章引用超過50次。其中於2014年發表在Clinical Cancer Research上的文章被評為特載形式（featured article）發表被著重推薦，成為Editor’s Picks。應邀多次在美國、歐洲、澳洲、亞洲等國家和地區舉行的國際會議上做學術報告。研究成果多次在國際國內會議上獲獎，包括 2013年英國國家腫瘤年會獎、21屆香港國際腫瘤會議最佳報告獎等。主持承擔多個國際國內科研項目，包括國家自然科學基金面上項目、香港研究資助局RGC研究基金、香港大學基礎研究基金、Raybiotech全球科研基金等。
主要經歷
1997~2003:本碩連讀：國家生命科學與技術人才培養基地，吉林大學/瀋陽藥科大學/中科院上海生化所；
2003~2004:國家人類基因組北方研究中心研究助理；
2004~2005:香港大學分子生物學研究所研究助理；
2005~2009:博士學位香港大學醫學院；
2009~2015:香港大學生物醫學學院、癌症研究中心博士後 ；
2015~至今:暨南大學副研究員。
研究方向
腫瘤分子細胞生物學：腫瘤相關新基因的功能篩選、鑑定及早期診斷、靶向治療研究等；
癌症蛋白質組學：套用蛋白質組學探討腫瘤分子標記物和藥物靶點的分子機制；
腫瘤微環境：腫瘤微環境在惡性腫瘤發展中的重要作用及功能機理研究。
1.腫瘤分子細胞生物學：腫瘤相關新基因的功能篩選、鑑定及早期診斷、靶向治療研究等；
2.癌症蛋白質組學：套用蛋白質組學探討腫瘤分子標記物和藥物靶點的分子機制；
3.腫瘤微環境：腫瘤微環境在惡性腫瘤發展中的重要作用及功能機理研究。
科研情況
暨南大學引進人才啟動基金，“結合疾病模型和蛋白質組學篩選腫瘤相關新基因的研究平台建立”,50萬元,2015-20172
國家自然科學基金面上項目,“miR-29c/FBXO31信號通路在食管癌耐藥機制中的調控作用及靶向治療”,74萬元,2015-2018
香港大學基礎研究基金，“SuppressiveeffectsofId1-targetingmicroRNAsinmetastasisofesophagealcancer”，HK$77,119,2013-2014
香港大學基礎研究基金，“PI3K/AKTpathwayasatherapeutictargetinhumanesophagealcancer”，HK$56,457,2011-2012
1.暨南大學引進人才啟動基金，“結合疾病模型和蛋白質組學篩選腫瘤相關新基因的研究平台建立”,50萬元,2015-20172
2.國家自然科學基金面上項目,“miR-29c/FBXO31信號通路在食管癌耐藥機制中的調控作用及靶向治療”,74萬元,2015-2018
3.香港大學基礎研究基金，“SuppressiveeffectsofId1-targetingmicroRNAsinmetastasisofesophagealcancer”，HK$77,119,2013-2014
4.香港大學基礎研究基金，“PI3K/AKTpathwayasatherapeutictargetinhumanesophagealcancer”，HK$56,457,2011-2012
學術論文
LiB#,XuWW#,GuanXY,QinYR,LawS,LeeNP,ChanKT,TamPY,LiYY,ChanKW,YuenHF,TsaoSW,HeQY,CheungAL(2015).CompetitivebindingbetweenId1andE2F1toCdc20regulatesE2F1degradationandtranscriptionalactivationofIGF2topromoteesophagealcancerchemoresistance.AcceptedbyClinicalCancerResearch.2015Sep15.(#共同第一作者)(影響因子=8.722，A1一區)
LiJ#,LiB#,XuWW,ChanKW,GuanXY,QinYR,LeeNP,ChanKT,LawS,TsaoSW,CheungAL(2015).RoleofAMPKsignalinginmediatingtheanti-cancereffectsofsilibinininesophagealsquamouscellcarcinoma.AcceptedbyExpertOpiniononTherapeuticTargets.2015Nov13.(#共同第一作者)(影響因子=5.139，A1二區)
XuWW,LiB,LamAKY,TsaoSW,ChanKW,CheungAL(2015).TargetingVEGFR1-andVEGFR2-expressingnon-tumorcellsisessentialforesophagealcancertherapy.Oncotarget.6(3):1790-1805.(影響因子=6.359，A1二區)
XuWW,LiB,CheungAL(2015).Thepotentialoftargetedanti-angiogenesistherapiesinthetreatmentofesophagealcancer.GastrointestinalCancer:TargetsandTherapy.5:79-88.(特邀綜述)
LiB,LiJ,XuWW,GuanXY,QinYR,ZhangLY,LawS,TsaoSW,CheungAL(2014).SuppressionofesophagealtumorgrowthandchemoresistancebydirectlytargetingthePI3K/AKTpathway.Oncotarget.5(22):11539-50.(影響因子=6.359，A1二區)
LiB,TsaoSW,ChanKW,LudwigDL,NovosyadlyyR,LiYY,HeQY,CheungAL(2014).Id1-inducedIGF2anditsautocrine/endocrinepromotionofesophagealcancergrowthandmetastasis-ImplicationsforIGF1R-targetedtherapy.ClinicalCancerResearch.20(10):2651-62.(影響因子=8.722，A1一區)(被推薦為特載形式發表Featuredarticle,AACREditor’sPicks,andMDLink)
LiuJ,HanL,LiB,YangJ,HuenMS,PanX,TsaoSW,CheungAL(2014).FBXO31negativelyregulatesp38mitogen-activatedprotein(MAP)kinasesignalingbymediatingk48-linkedubiquitinationanddegradationofMAPkinasekinase6(MKK6).TheJournalofBiologicalChemistry.289(31):21508-18.(影響因子=4.573，A1二區)
XuWW,LiB,LaiE,ChenL,HuangJJ,CheungAL,CheungPC(2014).TheinvivochemopreventiveanddrugresistanteffectstudyofhotwaterextractfromPleurotuepulmonarius.NutritionandCancer.66(6):989-98.(影響因子=2.322，A2區)
LiB,TsaoSW,LiYY,WangXH,LingMT,WongYC,HeQY,CheungAL.(2009)Id-1promotestumorigenicityandmetastasisofhumanesophagealcancercellsthroughactivationofPI3K/AKTsignalingpathway.Int.J.Cancer.125(11):2576-2585.(影響因子=5.085，A1二區)
LiB,LiYY,TsaoSW,CheungAL.(2009)Targetingnuclearfactor-kappaBsignalingpathwaysuppressestumorgrowth,angiogenesis,andmetastasisofhumanesophagealcancer.Mol.Cancer.Ther.8(9):2635-2644.(影響因子=5.683，A1二區)
LiB,CheungPY,WangX,TsaoSW,LingMT,WongYC,CheungAL(2007).Id-1activationofPI3K/Akt/NFkappaBsignalingpathwayanditssignificanceinpromotingsurvivalofesophagealcancercells.Carcinogenesis.28(11):2313-2320.(影響因子=5.334，A1二區)
JiaJ,LiB,JinYX,WangDB(2003).Expression,PurificationandCharacterizationofHumanTyrosyl-tRNASynthetase.ProteinExpressionandPurification.27:104-108.(影響因子=1.695，A3區)
LinJS,SongYH,KongXJ,LiB,LiuNZ,WuXL,JinYX(2003).Preparationandidentificationofanti-transforminggrowthfactor1U1smallnuclearRNAchimericribozymeinvitro.WorldJournalofGastroenterology9(3):572-7.(影響因子=2.369，A2區)
KongXJ,SongYH,LinJS,HuangHJ,WangNX,LiuNZ,LiB,JinYX(2003).Maxizyme-mediatedspecificinhibitiononmutant-typep53invitro.WorldJournalofGastroenterology9(7):1571-1575.(影響因子=2.369，A2區)
1.LiB#,XuWW#,GuanXY,QinYR,LawS,LeeNP,ChanKT,TamPY,LiYY,ChanKW,YuenHF,TsaoSW,HeQY,CheungAL(2015).CompetitivebindingbetweenId1andE2F1toCdc20regulatesE2F1degradationandtranscriptionalactivationofIGF2topromoteesophagealcancerchemoresistance.AcceptedbyClinicalCancerResearch.2015Sep15.(#共同第一作者)(影響因子=8.722，A1一區)
2.LiJ#,LiB#,XuWW,ChanKW,GuanXY,QinYR,LeeNP,ChanKT,LawS,TsaoSW,CheungAL(2015).RoleofAMPKsignalinginmediatingtheanti-cancereffectsofsilibinininesophagealsquamouscellcarcinoma.AcceptedbyExpertOpiniononTherapeuticTargets.2015Nov13.(#共同第一作者)(影響因子=5.139，A1二區)
3.XuWW,LiB,LamAKY,TsaoSW,ChanKW,CheungAL(2015).TargetingVEGFR1-andVEGFR2-expressingnon-tumorcellsisessentialforesophagealcancertherapy.Oncotarget.6(3):1790-1805.(影響因子=6.359，A1二區)
4.XuWW,LiB,CheungAL(2015).Thepotentialoftargetedanti-angiogenesistherapiesinthetreatmentofesophagealcancer.GastrointestinalCancer:TargetsandTherapy.5:79-88.(特邀綜述)
5.LiB,LiJ,XuWW,GuanXY,QinYR,ZhangLY,LawS,TsaoSW,CheungAL(2014).SuppressionofesophagealtumorgrowthandchemoresistancebydirectlytargetingthePI3K/AKTpathway.Oncotarget.5(22):11539-50.(影響因子=6.359，A1二區)
6.LiB,TsaoSW,ChanKW,LudwigDL,NovosyadlyyR,LiYY,HeQY,CheungAL(2014).Id1-inducedIGF2anditsautocrine/endocrinepromotionofesophagealcancergrowthandmetastasis-ImplicationsforIGF1R-targetedtherapy.ClinicalCancerResearch.20(10):2651-62.(影響因子=8.722，A1一區)(被推薦為特載形式發表Featuredarticle,AACREditor’sPicks,andMDLink)
7.LiuJ,HanL,LiB,YangJ,HuenMS,PanX,TsaoSW,CheungAL(2014).FBXO31negativelyregulatesp38mitogen-activatedprotein(MAP)kinasesignalingbymediatingk48-linkedubiquitinationanddegradationofMAPkinasekinase6(MKK6).TheJournalofBiologicalChemistry.289(31):21508-18.(影響因子=4.573，A1二區)
8.XuWW,LiB,LaiE,ChenL,HuangJJ,CheungAL,CheungPC(2014).TheinvivochemopreventiveanddrugresistanteffectstudyofhotwaterextractfromPleurotuepulmonarius.NutritionandCancer.66(6):989-98.(影響因子=2.322，A2區)
9.LiB,TsaoSW,LiYY,WangXH,LingMT,WongYC,HeQY,CheungAL.(2009)Id-1promotestumorigenicityandmetastasisofhumanesophagealcancercellsthroughactivationofPI3K/AKTsignalingpathway.Int.J.Cancer.125(11):2576-2585.(影響因子=5.085，A1二區)
10.LiB,LiYY,TsaoSW,CheungAL.(2009)Targetingnuclearfactor-kappaBsignalingpathwaysuppressestumorgrowth,angiogenesis,andmetastasisofhumanesophagealcancer.Mol.Cancer.Ther.8(9):2635-2644.(影響因子=5.683，A1二區)
11.LiB,CheungPY,WangX,TsaoSW,LingMT,WongYC,CheungAL(2007).Id-1activationofPI3K/Akt/NFkappaBsignalingpathwayanditssignificanceinpromotingsurvivalofesophagealcancercells.Carcinogenesis.28(11):2313-2320.(影響因子=5.334，A1二區)
12.JiaJ,LiB,JinYX,WangDB(2003).Expression,PurificationandCharacterizationofHumanTyrosyl-tRNASynthetase.ProteinExpressionandPurification.27:104-108.(影響因子=1.695，A3區)
13.LinJS,SongYH,KongXJ,LiB,LiuNZ,WuXL,JinYX(2003).Preparationandidentificationofanti-transforminggrowthfactor1U1smallnuclearRNAchimericribozymeinvitro.WorldJournalofGastroenterology9(3):572-7.(影響因子=2.369，A2區)
14.KongXJ,SongYH,LinJS,HuangHJ,WangNX,LiuNZ,LiB,JinYX(2003).Maxizyme-mediatedspecificinhibitiononmutant-typep53invitro.WorldJournalofGastroenterology9(7):1571-1575.(影響因子=2.369，A2區)
學術報告
Identification of miR-29c/FBXO31 as a key regulatory mechanism in esophageal cancer chemoresistance. In: International Conference on Antimicrobial Agents and Chemotherapy.2015 Aug 4-6; Valencia, Spain.
2. Functional identification, clinical relevance and therapeutic implication of genes/miRNAs involved in cancer chemoresistance and metastasis. 2015 Feb 4; Institute of Chinese Medical Sciences, University of Macau, Macau.
3. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. In: 2014 World Cancer Congress. Dec 3-6; Melbourne, Australia.
4. Id1/IGF2/PI3K/AKT signaling cascade as functional markers and therapeutic targets in esophageal cancer. In: Markers in Cancer. 2013 Nov 7-9; Brussels, Belgium.
5. Role of Id1-induced IGF2 in autocrine/endocrine promotion of esophageal cancer tumorigenesis and metastasis. In: Proceedings of American Association for Cancer Research Annual Meeting; 2012 Mar 31-Apr 4; Chicago, IL, USA.
6. PI3K/AKT pathway as a therapeutic target in human esophageal cancer. In: 21st Asia Pacific Cancer Conference; 2011 Nov 10-12; Kuala Lumpur, Malaysia.
7. PI3K/AKT pathway as a therapeutic target in human esophageal cancer. In: The Croucher Foundation Advanced Study Institute, Molecular Genetics and Clinical Advances in the Study of Esophageal and Gastric Cancers; 2011 Jan 23-27; The University of Hong Kong, Hong Kong.
Li B, Cheung PY, Wang XH, Tsao SW, Ling MT, Wong YC, Cheung LM (2007). Id-1 protects esophageal cancer cells from TNF-α-induced apoptosis through activation of PI3K/AKT/NFκB signaling pathway. In: Proceedings of American Association for Cancer Research Annual Meeting; 2007 Apr 14-18; Los Angeles, CA, USA. 研究生
1.Identification of miR-29c/FBXO31 as a key regulatory mechanism in esophageal cancer chemoresistance. In: International Conference on Antimicrobial Agents and Chemotherapy.2015 Aug 4-6; Valencia, Spain.
2.2. Functional identification, clinical relevance and therapeutic implication of genes/miRNAs involved in cancer chemoresistance and metastasis. 2015 Feb 4; Institute of Chinese Medical Sciences, University of Macau, Macau.
3.3. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. In: 2014 World Cancer Congress. Dec 3-6; Melbourne, Australia.
4.4. Id1/IGF2/PI3K/AKT signaling cascade as functional markers and therapeutic targets in esophageal cancer. In: Markers in Cancer. 2013 Nov 7-9; Brussels, Belgium.
5.5. Role of Id1-induced IGF2 in autocrine/endocrine promotion of esophageal cancer tumorigenesis and metastasis. In: Proceedings of American Association for Cancer Research Annual Meeting; 2012 Mar 31-Apr 4; Chicago, IL, USA.
6.6. PI3K/AKT pathway as a therapeutic target in human esophageal cancer. In: 21st Asia Pacific Cancer Conference; 2011 Nov 10-12; Kuala Lumpur, Malaysia.
7.7. PI3K/AKT pathway as a therapeutic target in human esophageal cancer. In: The Croucher Foundation Advanced Study Institute, Molecular Genetics and Clinical Advances in the Study of Esophageal and Gastric Cancers; 2011 Jan 23-27; The University of Hong Kong, Hong Kong.
8.Li B, Cheung PY, Wang XH, Tsao SW, Ling MT, Wong YC, Cheung LM (2007). Id-1 protects esophageal cancer cells from TNF-α-induced apoptosis through activation of PI3K/AKT/NFκB signaling pathway. In: Proceedings of American Association for Cancer Research Annual Meeting; 2007 Apr 14-18; Los Angeles, CA, USA. 研究生
招生專業方向
071010生物化學與分子生物學專業，03方向_功能蛋白質與蛋白質組學。
